The launch of HayloARC and the battle for oral GLP-1 pill supremacy
This episode focuses on two main health-related launches: HayloARC, a new health-focused demand-side platform, and the battle for oral GLP-1 pill supremacy between Novo Nordisk and Eli Lilly. The discussion covers HayloARC's features and differentiation, as well as recent…